<p>LENZ Therapeutics, Inc.（纳斯达克代码：LENZ - 获取免费报告）的股票在目前覆盖该股票的七家券商中获得了 “适度买入” 的平均推荐，MarketBeat Ratings 报告称。一位研究分析师对该股票给予了卖出推荐，一位给予了持有推荐，五位则对该公司给予了买入推荐。在过去一年中更新了对该股票覆盖的券商中，12 个月的平均目标价格为 56.40 美元。</p>
<p>获取 <strong>LENZ Therapeutics</strong> 的提醒：</p>
<p>多家研究公司最近对 LENZ 进行了评估。Piper Sandler 将 LENZ Therapeutics 的目标价格上调至 67.00 美元，并在 10 月 10 日的研究报告中给予该公司 “超配” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 LENZ Therapeutics 股票的 “卖出（d-）” 评级。Raymond James Financial 在 10 月 20 日的研究报告中重申了 “跑赢大盘” 评级，并将 LENZ Therapeutics 股票的目标价格上调至 50.00 美元（之前为 40.00 美元）。Zacks Research 在 11 月 20 日的研究报告中将 LENZ Therapeutics 股票的评级从 “强力买入” 下调至 “持有”。最后，HC Wainwright 在 12 月 15 日的报告中重申了对 LENZ Therapeutics 股票的 “买入” 评级。</p>
<p><strong>查看我们对 LENZ Therapeutics 的最新股票分析</strong></p>
<h2>LENZ Therapeutics 的内部交易</h2>
<p>在相关消息中，内部人士 Shawn Olsson 于 11 月 17 日星期一出售了 10,000 股该公司的股票。股票以平均价格 26.10 美元出售，总价值为 261,000.00 美元。出售后，该内部人士直接持有该公司 4,733 股股票，价值 123,531.30 美元。此次交易使其持股减少了 67.87%。该交易已在证券交易委员会的备案中披露，相关信息可在此链接查看。此外，董事 James W. Mccollum 于 11 月 7 日星期五购买了 10,500 股该公司的股票。股票以每股平均价格 22.79 美元收购，总价值为 239,295.00 美元。完成收购后，该董事直接持有该公司 10,500 股股票，价值 239,295 美元。这代表其持股增加了∞。有关此次购买的更多细节可在官方 SEC 披露中找到。公司内部人士持有该公司 6.90% 的股份。</p>
<h2>对 LENZ Therapeutics 的对冲基金看法</h2>
<p>几家对冲基金最近买入和卖出了 LENZ 的股票。Intech Investment Management LLC 在第二季度将其在 LENZ Therapeutics 的持股增加了 4.3%。Intech Investment Management LLC 目前持有该公司 9,251 股股票，价值 271,000 美元，此前在上个季度又购买了 380 股。Tower Research Capital LLC TRC 在第二季度将其在 LENZ Therapeutics 的持股增加了 51.4%。Tower Research Capital LLC TRC 目前持有该公司 1,405 股股票，价值 41,000 美元，此前在上个季度又购买了 477 股。Quarry LP 在第三季度以约 27,000 美元的价格获得了 LENZ Therapeutics 的新头寸。Ameritas Investment Partners Inc. 在第二季度将其在 LENZ Therapeutics 的持股增加了 47.6%。Ameritas Investment Partners Inc. 目前持有该公司 1,817 股股票，价值 53,000 美元，此前在上个季度又购买了 586 股。最后，Bfsg LLC 在第三季度以约 30,000 美元的价格购买了 LENZ Therapeutics 的新股份。对冲基金和其他机构投资者持有该公司 54.32% 的股份。</p>
<h2>LENZ Therapeutics 股票表现</h2>
<p>LENZ Therapeutics 股票在星期五开盘价为 14.87 美元。LENZ Therapeutics 的一年低点为 14.84 美元，一年高点为 50.40 美元。该公司的市值为 4.6528 亿美元，市盈率为-7.05，贝塔值为 0.50。该公司的 50 日移动平均线为 22.71 美元，200 日移动平均线为 31.95 美元。</p>
<p>LENZ Therapeutics（纳斯达克代码：LENZ - 获取免费报告）最近于 11 月 5 日星期三发布了季度财报。该公司报告每股收益（EPS）为（0.59）美元，超出分析师一致预期的（0.67）美元，超出幅度为 0.08 美元。该公司季度收入为 1250 万美元，而分析师预期为 464 万美元。整体来看，股票分析师预测 LENZ Therapeutics 本年度每股收益为-2.18 美元。</p>
<h2>LENZ Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>LENZ Therapeutics, Inc. 是一家生物制药公司，专注于开发和商业化改善美国视力的疗法。其产品候选包括 LNZ100 和 LNZ101，目前正在进行治疗老花眼的第三阶段临床试验。该公司总部位于加利福尼亚州德尔玛。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 LENZ Therapeutics 更好</li>
<li>埃隆将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>股票代码揭晓：首次公开募股接入 “下一个埃隆·马斯克” 公司</li>
<li>自 2007 年以来首次：所有警告均已激活</li>
<li>富人如何退休</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUxFTlo?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUxFTlo"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 LENZ Therapeutics 吗？</h2>
<p>在考虑 LENZ Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 LENZ Therapeutics 并不在名单上。</p>
<p>虽然 LENZ Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LENZ

<p>LENZ Therapeutics, Inc.（纳斯达克代码：LENZ）获得了七家券商的 “适度买入” 共识评级。12 个月的平均目标价格为 56.40 美元，Piper Sandler 设定的目标为 67.00 美元。内部交易包括 Shawn Olsson 出售 10,000 股和董事 James W. Mccollum 购买 10,500 股。该股票开盘价为 14.87 美元，市值为 4.6528 亿美元。LENZ 报告每股收益为（0.59 美元），超出预期，上一季度的收入为 1250 万美元</p>

<p>Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned an average recommendation of &#34;Moderate Buy&#34; from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $56.40.</p>
<div class="lb-trans"><p>LENZ Therapeutics, Inc.（纳斯达克代码：LENZ - 获取免费报告）的股票在目前覆盖该股票的七家券商中获得了 “适度买入” 的平均推荐，MarketBeat Ratings 报告称。一位研究分析师对该股票给予了卖出推荐，一位给予了持有推荐，五位则对该公司给予了买入推荐。在过去一年中更新了对该股票覆盖的券商中，12 个月的平均目标价格为 56.40 美元。</p>
</div><p>Get <strong>LENZ Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>LENZ Therapeutics</strong> 的提醒：</p>
</div><p>A number of research firms recently weighed in on LENZ. Piper Sandler lifted their price target on LENZ Therapeutics to $67.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, October 10th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of LENZ Therapeutics in a research note on Wednesday, October 8th. Raymond James Financial reiterated an &#34;outperform&#34; rating and issued a $50.00 price objective (up previously from $40.00) on shares of LENZ Therapeutics in a research note on Monday, October 20th. Zacks Research lowered shares of LENZ Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, November 20th. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating on shares of LENZ Therapeutics in a report on Monday, December 15th.</p>
<div class="lb-trans"><p>多家研究公司最近对 LENZ 进行了评估。Piper Sandler 将 LENZ Therapeutics 的目标价格上调至 67.00 美元，并在 10 月 10 日的研究报告中给予该公司 “超配” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 LENZ Therapeutics 股票的 “卖出（d-）” 评级。Raymond James Financial 在 10 月 20 日的研究报告中重申了 “跑赢大盘” 评级，并将 LENZ Therapeutics 股票的目标价格上调至 50.00 美元（之前为 40.00 美元）。Zacks Research 在 11 月 20 日的研究报告中将 LENZ Therapeutics 股票的评级从 “强力买入” 下调至 “持有”。最后，HC Wainwright 在 12 月 15 日的报告中重申了对 LENZ Therapeutics 股票的 “买入” 评级。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on LENZ Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 LENZ Therapeutics 的最新股票分析</strong></p>
</div><h2>Insider Transactions at LENZ Therapeutics</h2>
<div class="lb-trans"><h2>LENZ Therapeutics 的内部交易</h2>
</div><p>In related news, insider Shawn Olsson sold 10,000 shares of the business's stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $26.10, for a total value of $261,000.00. Following the sale, the insider directly owned 4,733 shares in the company, valued at $123,531.30. The trade was a 67.87% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, Director James W. Mccollum bought 10,500 shares of the company's stock in a transaction on Friday, November 7th. The shares were acquired at an average price of $22.79 per share, with a total value of $239,295.00. Following the completion of the acquisition, the director directly owned 10,500 shares in the company, valued at $239,295. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 6.90% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Shawn Olsson 于 11 月 17 日星期一出售了 10,000 股该公司的股票。股票以平均价格 26.10 美元出售，总价值为 261,000.00 美元。出售后，该内部人士直接持有该公司 4,733 股股票，价值 123,531.30 美元。此次交易使其持股减少了 67.87%。该交易已在证券交易委员会的备案中披露，相关信息可在此链接查看。此外，董事 James W. Mccollum 于 11 月 7 日星期五购买了 10,500 股该公司的股票。股票以每股平均价格 22.79 美元收购，总价值为 239,295.00 美元。完成收购后，该董事直接持有该公司 10,500 股股票，价值 239,295 美元。这代表其持股增加了∞。有关此次购买的更多细节可在官方 SEC 披露中找到。公司内部人士持有该公司 6.90% 的股份。</p>
</div><h2>Hedge Funds Weigh In On LENZ Therapeutics</h2>
<div class="lb-trans"><h2>对 LENZ Therapeutics 的对冲基金看法</h2>
</div><p>Several hedge funds have recently bought and sold shares of LENZ. Intech Investment Management LLC lifted its position in shares of LENZ Therapeutics by 4.3% in the second quarter. Intech Investment Management LLC now owns 9,251 shares of the company's stock valued at $271,000 after acquiring an additional 380 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in LENZ Therapeutics by 51.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company's stock valued at $41,000 after purchasing an additional 477 shares during the last quarter. Quarry LP acquired a new position in LENZ Therapeutics in the 3rd quarter valued at about $27,000. Ameritas Investment Partners Inc. boosted its stake in shares of LENZ Therapeutics by 47.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,817 shares of the company's stock worth $53,000 after purchasing an additional 586 shares during the last quarter. Finally, Bfsg LLC purchased a new stake in shares of LENZ Therapeutics during the third quarter worth about $30,000. Hedge funds and other institutional investors own 54.32% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近买入和卖出了 LENZ 的股票。Intech Investment Management LLC 在第二季度将其在 LENZ Therapeutics 的持股增加了 4.3%。Intech Investment Management LLC 目前持有该公司 9,251 股股票，价值 271,000 美元，此前在上个季度又购买了 380 股。Tower Research Capital LLC TRC 在第二季度将其在 LENZ Therapeutics 的持股增加了 51.4%。Tower Research Capital LLC TRC 目前持有该公司 1,405 股股票，价值 41,000 美元，此前在上个季度又购买了 477 股。Quarry LP 在第三季度以约 27,000 美元的价格获得了 LENZ Therapeutics 的新头寸。Ameritas Investment Partners Inc. 在第二季度将其在 LENZ Therapeutics 的持股增加了 47.6%。Ameritas Investment Partners Inc. 目前持有该公司 1,817 股股票，价值 53,000 美元，此前在上个季度又购买了 586 股。最后，Bfsg LLC 在第三季度以约 30,000 美元的价格购买了 LENZ Therapeutics 的新股份。对冲基金和其他机构投资者持有该公司 54.32% 的股份。</p>
</div><h2>LENZ Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>LENZ Therapeutics 股票表现</h2>
</div><p>Shares of LENZ Therapeutics stock opened at $14.87 on Friday. LENZ Therapeutics has a one year low of $14.84 and a one year high of $50.40. The company has a market cap of $465.28 million, a P/E ratio of -7.05 and a beta of 0.50. The firm has a fifty day moving average of $22.71 and a two-hundred day moving average of $31.95.</p>
<div class="lb-trans"><p>LENZ Therapeutics 股票在星期五开盘价为 14.87 美元。LENZ Therapeutics 的一年低点为 14.84 美元，一年高点为 50.40 美元。该公司的市值为 4.6528 亿美元，市盈率为-7.05，贝塔值为 0.50。该公司的 50 日移动平均线为 22.71 美元，200 日移动平均线为 31.95 美元。</p>
</div><p>LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.08. The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $4.64 million. As a group, equities analysts predict that LENZ Therapeutics will post -2.18 earnings per share for the current year.</p>
<div class="lb-trans"><p>LENZ Therapeutics（纳斯达克代码：LENZ - 获取免费报告）最近于 11 月 5 日星期三发布了季度财报。该公司报告每股收益（EPS）为（0.59）美元，超出分析师一致预期的（0.67）美元，超出幅度为 0.08 美元。该公司季度收入为 1250 万美元，而分析师预期为 464 万美元。整体来看，股票分析师预测 LENZ Therapeutics 本年度每股收益为-2.18 美元。</p>
</div><h2>LENZ Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>LENZ Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.</p>
<div class="lb-trans"><p>LENZ Therapeutics, Inc. 是一家生物制药公司，专注于开发和商业化改善美国视力的疗法。其产品候选包括 LNZ100 和 LNZ101，目前正在进行治疗老花眼的第三阶段临床试验。该公司总部位于加利福尼亚州德尔玛。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than LENZ Therapeutics</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li>
<li>First Time Since 2007: All Warnings Active</li>
<li>How the Rich Retire</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 LENZ Therapeutics 更好</li>
<li>埃隆将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>股票代码揭晓：首次公开募股接入 “下一个埃隆·马斯克” 公司</li>
<li>自 2007 年以来首次：所有警告均已激活</li>
<li>富人如何退休</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEVOWg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=LENZ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in LENZ Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 LENZ Therapeutics 吗？</h2>
</div><p>Before you consider LENZ Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 LENZ Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 LENZ Therapeutics 并不在名单上。</p>
</div><p>While LENZ Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 LENZ Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

LENZ Therapeutics, Inc. (NASDAQ:LENZ) 被多家券商一致评为 “适度买入”